Factors Involved in the Regulation of
Gastrointestinal Motility, Hormone Release,
Symptoms and Energy Intake in Health and
Patients with Functional Dyspepsia

A thesis submitted by
Amelia Pilichiewicz

For the degree of
Doctor of Philosophy

Discipline of Medicine
University of Adelaide

January 2008
# TABLE OF CONTENTS

LIST OF ABBREVIATIONS .................................................................................. I  
THESIS SUMMARY .......................................................................................... III  
DECLARATION OF ORIGINALITY .................................................................. IX  
DEDICATION ...................................................................................................... X  
ACKNOWLEDGEMENTS .................................................................................. XI  
PUBLICATIONS ARISING FROM THIS THESIS ............................................ XIV  

Chapter 1  
EFFECTS OF NUTRIENTS ON THE GASTROINTESTINAL TRACT, GASTROINTESTINAL HORMONE RELEASE AND ENERGY INTAKE

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td>1.2</td>
<td>ANATOMY AND FUNCTION OF THE GASTROINTESTINAL TRACT</td>
<td>2</td>
</tr>
<tr>
<td>1.2.1</td>
<td>Stomach</td>
<td>2</td>
</tr>
<tr>
<td>1.2.2</td>
<td>Pylorus</td>
<td>2</td>
</tr>
<tr>
<td>1.2.3</td>
<td>Small intestine</td>
<td>3</td>
</tr>
<tr>
<td>1.3</td>
<td>GASTROINTESTINAL MOTOR FUNCTION AND ITS ROLE IN GASTRIC SENSATIONS, APPETITE AND ENERGY INTAKE</td>
<td>4</td>
</tr>
<tr>
<td>1.3.1</td>
<td>Fasting motor patterns</td>
<td>4</td>
</tr>
<tr>
<td>1.3.2</td>
<td>Fed motor patterns</td>
<td>5</td>
</tr>
</tbody>
</table>
Chapter 2

FUNCTIONAL DYSPEPSIA

2.1 INTRODUCTION ................................................................. 38

2.2 DEFINITION OF FUNCTIONAL DYSPEPSIA ....................... 39

2.3 PREVALENCE AND COSTS OF FUNCTIONAL DYSPEPSIA .... 40
## 2.4 PATHOPHYSIOLOGY OF FUNCTIONAL DYSPEPSIA -

**RELATIONSHIP TO GASTROINTESTINAL FUNCTION** .............................................. 42

2.4.1 *Helicobacter pylori* and acid secretion .................................................. 42

2.4.2 Delayed gastric emptying ........................................................................... 43

2.4.3 Intragastric meal distribution .................................................................... 45

2.4.4 Impaired gastric relaxation ........................................................................ 46

2.4.5 Dysfunction of the antrum ....................................................................... 48

2.4.6 Integration of proximal and distal gastric function ................................. 50

2.4.7 Visceral hypersensitivity ......................................................................... 51

## 2.5 ROLE OF DIET ............................................................................................. 52

2.5.1 Food intolerance ....................................................................................... 53

2.5.2 Patterns of food ingestion ......................................................................... 53

2.5.3 Influence of individual macronutrients on symptoms ............................ 54

## 2.6 GASTROINTESTINAL HORMONE RELEASE AND SUPPRESSION .... 57

## 2.7 COGNITIVE INFLUENCES ........................................................................ 58

## 2.8 SUMMARY .................................................................................................. 61

## Chapter 3

### TREATMENT OPTIONS FOR FUNCTIONAL DYSPEPSIA

3.1 **INTRODUCTION** .............................................................................................. 62

3.2 **COMMON PHARMACOTHERAPIES USED FOR THE TREATMENT OF**

**FUNCTIONAL DYSPEPSIA** .............................................................................. 64

3.2.1 Prokinetics .................................................................................................. 64

3.2.2 Fundus-relaxing agents ............................................................................ 70
3.2.3 Antisecretory drugs and antacids ........................................................... 71
3.2.4 *Helicobacter pylori* eradication ............................................................. 73
3.2.5 Tricyclic antidepressants ........................................................................ 74

3.3 NON-PHARMACOLOGICAL THERAPY AND ALTERNATIVE MEDICINES ............................................................................................... 76

3.3.1 Acupuncture ........................................................................................... 76
3.3.2 Hypnotherapy .......................................................................................... 77

3.4 HERBAL PREPARATIONS ....................................................................... 78

3.4.1 Clinical trials of mono-preparations ...................................................... 79
3.4.2 Clinical trials of combination preparations ............................................ 82
3.4.3 Iberogast® .............................................................................................. 85

3.5 SUMMARY ................................................................................................. 96

Chapter 4

COMMON METHODOLOGIES

4.1 INTRODUCTION .......................................................................................... 98

4.2 SUBJECTS ..................................................................................................... 98

4.2.1 Subject recruitment ................................................................................ 98
4.2.2 Common exclusion criteria ................................................................... 100
4.2.3 Additional exclusion criteria for functional dyspepsia patients ......... 100

4.3 ETHICS COMMITTEE APPROVAL .......................................................... 101

4.4 STUDY TREATMENTS .............................................................................. 101

4.4.1 Yoghurt preloads .................................................................................. 101
4.4.2 Intraduodenal infusions ......................................................................... 104
Chapter 5

EFFECTS OF LOAD, AND DURATION, OF DUODENAL LIPID ON GUT MOTILITY, PLASMA CCK AND PYY AND ENERGY INTAKE IN HEALTHY MEN

5.1 SUMMARY ........................................................................................................ 127
5.2 INTRODUCTION ............................................................................................. 128
5.3 SUBJECTS AND METHODS ......................................................................... 131
5.3.1 Subjects .................................................................................................... 131
5.3.2 Study outline ............................................................................................ 131
5.3.3 Intraduodenal infusions .......................................................................... 131
Chapter 6

LOAD-DEPENDENT EFFECTS OF DUODENAL LIPID ON ANTROPYLORODUODENAL MOTILITY, PLASMA CCK AND PYY, AND ENERGY INTAKE IN HEALTHY MEN

6.1 SUMMARY .............................................................................................................. 159
6.2 INTRODUCTION .................................................................................................... 160
6.3 SUBJECTS AND METHODS ................................................................................ 162
  6.3.1 Subjects ........................................................................................................... 162
  6.3.2 Study outline ................................................................................................ 162
  6.3.3 Intraduodenal infusions .............................................................................. 162
  6.3.4 Protocol .......................................................................................................... 163
  6.3.5 Measurements .............................................................................................. 164
7.3.4  Protocol................................................................................................ 192
7.3.5  Measurements ...................................................................................... 193
7.3.6  Statistical analysis................................................................................ 194
7.4  RESULTS .................................................................................................... 196
  7.4.1  Blood glucose and plasma hormone concentrations....................... 196
  7.4.2  Antropyloroduodenal pressures ........................................................... 200
  7.4.3  Energy intake ....................................................................................... 203
  7.4.4  Relations between antropyloroduodenal motility, blood glucose,
         hormones and energy intake ................................................................................. 203
  7.4.5  Predictors of insulin concentrations and energy intake ....................... 205
7.5  DISCUSSION .............................................................................................. 212
7.6  CONCLUSIONS ......................................................................................... 218

Chapter 8

IN FUNCTIONAL DYSPESIA ORAL CARBOHYDRATE AND
FAT DIFFERENTIALLY MODULATE SYMPTOMS, GUT
HORMONES AND ANTRAL AREA

8.1  SUMMARY .................................................................................................. 219
8.2  INTRODUCTION ........................................................................................ 220
8.3  SUBJECTS AND METHODS .................................................................... 223
  8.3.1  Subjects................................................................................................ 223
  8.3.2  Study outline........................................................................................ 223
  8.3.3  Preloads................................................................................................ 223
## Chapter 8

### RESULTS

8.4.1 Gastrointestinal symptoms and appetite perceptions ........................................ 226
8.4.2 Blood glucose and plasma hormone concentrations ........................................... 228
8.4.3 Antral area ........................................................................................................ 233
8.4.4 Energy intake .................................................................................................. 234
8.4.5 Relations between symptoms, appetite-related sensations, blood glucose, plasma hormones, antral area and energy intake .................................................. 234

### DISCUSSION

8.5 ......................................................................................................................... 242

### CONCLUSIONS

8.6 ......................................................................................................................... 247

## Chapter 9

### RELATIONSHIP BETWEEN DYSPEPTIC SYMPTOMS AND DIETARY PATTERNS IN FUNCTIONAL DYSPEPSIA

9.1 SUMMARY ..................................................................................................... 248
9.2 INTRODUCTION ............................................................................................ 249
9.3 SUBJECTS AND METHODS ......................................................................... 251
9.3.1 Subjects ..................................................................................................... 251
9.3.2 Protocol ..................................................................................................... 252
9.3.3 Measurements .......................................................................................... 252
9.3.4 Data and statistical analysis ...................................................................... 254
9.4 RESULTS ....................................................................................................... 255
Chapter 10

EFFECTS OF THE HERBAL MEDICATION, IBEROGAST® ON PROXIMAL GASTRIC VOLUME, ANTROPYLORODUODENAL MOTILITY AND GASTRIC EMPTYING IN HEALTHY MEN

10.1 SUMMARY ........................................................................................................ 269
10.2 INTRODUCTION ............................................................................................ 270
10.3 MATERIALS AND METHODS ......................................................................... 272
  10.3.1 Subjects ...................................................................................................... 272
  10.3.2 Study outline ............................................................................................. 272
  10.3.3 Composition of Iberogast® and preparation of control solution ............... 273
  10.3.4 Protocol .................................................................................................... 273
  10.3.5 Statistical analysis ..................................................................................... 276
10.4 RESULTS ......................................................................................................... 276
10.4.1 Part A: Effect of Iberogast® on intrabag volume changes (“gastric relaxation”) ........................................................................................................... 277
10.4.2 Part B: Effect of Iberogast® on antropyloroduodenal motility ...... 277
10.4.3 Part C: Effect of Iberogast® on gastric emptying and intragastric distribution ............................................................................................................ 279
10.5 DISCUSSION .......................................................................................................................... 287
10.6 CONCLUSIONS ..................................................................................................................... 290

Chapter 11

CONCLUSIONS .......................................................................................................................... 291

APPENDICES

APPENDIX 1: DIET DIARY ........................................................................................................ 298
APPENDIX 2: VISUAL ANALOGUE SCALE A ........................................................................ 299
APPENDIX 3: VISUAL ANALOGUE SCALE B ........................................................................ 300
APPENDIX 4: THREE FACTOR EATING QUESTIONNAIRE .............................................. 301
APPENDIX 5: EATING ATTITUDES TEST ........................................................................... 307
APPENDIX 6: NWRLC FAT INTAKE SCALE ........................................................................... 308
APPENDIX 7: NEPEAN DYSPEPSIA INDEX ........................................................................... 310
APPENDIX 8: EYSENCK ........................................................................................................ 319
APPENDIX 9: HAD (VI) ........................................................................................................... 320
APPENDIX 10: ZUNG SELF-RATING SCALE ....................................................................... 322
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.33/50</td>
<td>1.33 kcal/min lipid infusion for 50 min</td>
</tr>
<tr>
<td>1.33/150</td>
<td>1.33 kcal/min lipid infusion for 150 min</td>
</tr>
<tr>
<td>4/50</td>
<td>4 kcal/min lipid infusion for 50 min</td>
</tr>
<tr>
<td>5HT</td>
<td>5-Hydroxy-tryptamine</td>
</tr>
<tr>
<td>APD</td>
<td>antropyloroduodenal</td>
</tr>
<tr>
<td>ALE</td>
<td>artichoke leaf extract</td>
</tr>
<tr>
<td>ANOVA</td>
<td>analysis of variance</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the curve</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>CCK</td>
<td>cholecystokinin</td>
</tr>
<tr>
<td>CHO</td>
<td>carbohydrate</td>
</tr>
<tr>
<td>CV</td>
<td>coefficient of variation</td>
</tr>
<tr>
<td>EAT</td>
<td>Eating Attitudes Test</td>
</tr>
<tr>
<td>EPQ</td>
<td>Eysenck Personality Questionnaire</td>
</tr>
<tr>
<td>FD</td>
<td>functional dyspepsia</td>
</tr>
<tr>
<td>G1</td>
<td>1 kcal/min glucose infusion</td>
</tr>
<tr>
<td>G2</td>
<td>2 kcal/min glucose infusion</td>
</tr>
<tr>
<td>G4</td>
<td>4 kcal/min glucose infusion</td>
</tr>
<tr>
<td>GIP</td>
<td>glucose-dependent insulino-tropic polypeptide</td>
</tr>
<tr>
<td>GIS</td>
<td>gastrointestinal symptom</td>
</tr>
<tr>
<td>GLP-1</td>
<td>glucagon-like peptide-1</td>
</tr>
<tr>
<td>HAD</td>
<td>Hospital Anxiety and Depression</td>
</tr>
<tr>
<td>H pylori</td>
<td>Helicobacter pylori</td>
</tr>
</tbody>
</table>
HS: healthy subject
IBS: irritable bowel syndrome
IPPW: isolated pyloric pressure wave
IL0.25: 0.25 kcal/min lipid infusion
IL1.5: 1 kcal/min lipid infusion
Il4: 4 kcal/min lipid infusion
MI: motility index
MDP: minimal distending pressure
MMC: migrating motor complex
NDI: Nepean Dyspepsia Index
NS: not significant
NWLRC: Northwest Lipid Research Clinic
PWs: pressure waves
PWSs: pressure wave sequences
PYY: peptide tyrosine tyrosine
RMP: resting membrane potential
TFEQ: Three Factor Eating Questionnaire
THL: tetrahydrolipstatin
TMPD: transmucosal potential difference
VAS: visual analogue scale
THESIS SUMMARY

This thesis presents studies relating to effects of different macronutrients, predominantly fat and carbohydrate, on gastrointestinal motility, hormone release/suppression, appetite and energy intake in healthy subjects, and on symptom generation in patients with functional dyspepsia. The three broad areas that have been investigated in these studies are: (i) the effect of load, and duration, of small intestinal nutrient exposure on gastric motility, gastrointestinal hormone release/suppression, appetite and energy intake in healthy subjects, (ii) the dietary factors that may contribute to symptom generation in patients with functional dyspepsia, through analysis of diet diaries and acute nutrient challenges, and (iii) the effects of the herbal medication, Iberogast®, on gastric motility in healthy subjects.

The ingestion of nutrients, triggers a number of gastrointestinal responses, including the modulation of antropyloroduodenal motility, gastrointestinal hormone release/suppression, and the suppression of appetite and energy intake, resulting in a slowing of gastric emptying to an average rate of 1 - 3 kcal/min, which is required for efficient nutrient digestion and absorption. Additionally, the rate at which glucose enters the small intestine influences postprandial glycaemia and incretin responses. These responses have been demonstrated in animals to be dependent on the length, and region, of the small intestine exposed to fat and glucose, however, this has not been directly investigated in humans.

Functional dyspepsia is a clinical condition, characterised by chronic upper abdominal symptoms, such as nausea, bloating and early fullness, without a known cause, which
affects approximately 11 - 29 % of the population. Many studies have reported that disturbed gastric motor activity may be the cause of these symptoms, but patients frequently experience symptoms following ingestion of food, and some patients report to eat smaller meals more frequently and avoid fatty and spicy foods. In addition, laboratory-based studies have indicated that functional dyspepsia patients may be hypersensitive to fat, but not carbohydrate. To date, the treatments used to reduce symptoms are frequently directed at the normalisation of gastroduodenal motility, using prokinetics. However, the beneficial effect of these drugs is relatively small and variable, and their adverse effects can be substantial. Herbal drug preparations have recently received considerable interest as an alternative treatment option in functional dyspepsia. A commercially available herbal preparation, Iberogast® which contains nine plant extracts, has been reported to improve upper abdominal symptoms in functional dyspepsia and to decrease fundic tone, increase antral contractility and decrease afferent nerve sensitivity in experimental animals. The effects of Iberogast® in the human gastrointestinal tract have not been investigated.

The first three studies presented in this thesis have focused on the effects of delivering fat and glucose into the small intestine at different loads (Chapter 5, 6 and 7), lower, comparable to, and higher than gastric emptying normally occurs, and at different durations of infusion (but still at similar caloric loads - Chapter 5, fat only), on gastrointestinal motility, plasma hormone release/suppression, glycaemia, and energy intake in healthy male subjects.

The study in Chapter 5 demonstrated that antral pressure waves and pressure wave sequences were suppressed, and basal pyloric pressure, isolated pyloric pressure waves,
and plasma cholecystokinin and peptide YY stimulated, during both the low (1.33 kcal/min for 50 min: 67 kcal/min), and high (4 kcal/min for 50 min: 200 kcal), loads of lipid. The effect of the 4 kcal/min load was sustained so that the suppression of antral pressure waves and pressure wave sequences and increase in peptide YY remained evident after cessation of the infusion. The prolonged lipid infusion (1.33 kcal/min for 150 min: 200 kcal) suppressed antral pressure waves, stimulated cholecystokinin and peptide YY and basal pyloric pressure and tended to stimulate isolated pyloric pressure waves when compared with saline throughout the entire infusion period. These results indicate that both the load, and duration, of small intestinal lipid have an influence on antropyloroduodenal motility and patterns of cholecystokinin and peptide YY release.

Chapter 6 demonstrated that lipid loads lower than gastric emptying normally occurs (0.25 kcal/min for 50 min: 12.5 kcal) transiently stimulated isolated pyloric pressure waves and cholecystokinin release and suppressed pressure wave sequences and hunger scores. Loads comparable to (1.5 kcal/min for 50 min: 75 kcal) and higher (4 kcal/min for 50 min: 200 kcal), than the normal rate of gastric emptying, were required to stimulate basal pyloric tone and peptide YY release and suppress antral and duodenal pressure waves. Only the 4 kcal/min load suppressed energy intake. The effects of lipid on all parameters, with the exception of hunger, were load-dependent. In addition, there were relationships between antropyloroduodenal motility and cholecystokinin and peptide YY concentrations with energy/food intake.

The study in Chapter 7 demonstrated that loads of glucose lower than (1 kcal/min for 120 min: 120 kcal), comparable to (2 kcal/min for 120 min: 240 kcal) and higher than (4 kcal/min for 120 min: 480 kcal) the rate gastric emptying normally occurs, stimulated
blood glucose, plasma insulin, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and cholecystokinin concentrations and suppressed the number of antral pressure waves, 2 and 4 kcal/min loads were required for the suppression of duodenal pressure waves and pressure wave sequences and the stimulation of basal pyloric pressure and suppression of energy intake only after the 4 kcal/min loads. There were also relationships between glucagon-like peptide-1 and glucose-dependent insulinotropic peptide with basal pyloric tone, and food/energy intake with pyloric pressures.

The studies presented in the subsequent three chapters investigated the contribution of dietary factors on the generation of symptoms in patients with functional dyspepsia when compared with healthy subjects (Chapter 8 and 9) and the effect of Iberogast® on motility in the healthy gastrointestinal tract (Chapter 10). The effects of equi-caloric high-carbohydrate vs. high-fat yoghurt preloads on symptom generation, plasma hormone concentrations, antral area and energy intake were compared between functional dyspepsia patients and healthy subjects (Chapter 8). Nausea and pain were greater in patients after the high-fat, when compared with high-carbohydrate and control, preloads and with healthy subjects. Discomfort was greater after all preloads in patients when compared with healthy subjects. Fasting cholecystokinin and stimulation of cholecystokinin by the high-fat preload were greater in patients, while fasting and postprandial peptide YY were lower in patients than in healthy subjects, with no differences in fasting, or postprandial, plasma ghrelin between patients and healthy subjects. Fasting antral area was greater in patients, with no differences postprandially between patients and healthy subjects. There were no differences in energy intake between the two groups. The relationship between the effect of dietary intake and
eating behaviour over a 7-day period on the occurrence and severity of abdominal symptoms was compared between patients and healthy subjects (Chapter 9). The symptoms experienced by the patients included nausea, fullness discomfort, bloating and upper abdominal, and epigastric, pain, of a modest severity, which occurred within 30 min of eating. The number of “meals” ingested was significantly less in functional dyspepsia patients and there was a trend for total energy and fat intake to be less. The occurrence of these symptoms was also statistically related to the ingestion of fat and energy intake. The results of these studies indicate that diet, particularly the ingestion of fat, influences the development of symptoms in a subgroup of patients with functional dyspepsia.

The study in Chapter 10 evaluated the effect of the herbal drug Iberogast® on gastric motility in the gastrointestinal tract. Iberogast® increased proximal gastric volume, increased antral pressure waves without affecting pyloric or duodenal pressures, and slightly increased the retention of liquid in the total stomach, but had no effect on gastric emptying of solids or intragastric distribution. These results demonstrate that Iberogast® affects gastric motility in humans, and the stimulation of gastric relaxation and antral motility may contribute to the reported therapeutic efficacy of Iberogast® in functional dyspepsia.

The studies reported in this thesis provide new information about the regulation of gastric motility, hormone release/suppression, appetite and energy intake, by varying the loads of lipid and glucose infused into the small intestine in healthy subjects, which may have implications in patients with altered gastric motor functions, such as obese, type-2 diabetes and functional dyspepsia patients. In addition, studies in functional
dyspepsia patients revealed that diet, in particular the ingestion of fat, contribute to the cause of their symptoms, and these findings may have important implications for the development of diet-based therapies for the treatment of functional dyspepsia. Furthermore, functional dyspepsia patients with impaired gastric relaxation and antral dysmotility may benefit from the effects of Iberogast® as demonstrated in the healthy gastrointestinal tract.
DECLARATION OF ORIGINALITY

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis being made available in the University Library.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder/s of these works.

__________________________________

Amelia Pilichiewicz

January 2008
DEDICATION

To all my rocks...

You know who you are...

I am forever grateful...
ACKNOWLEDGEMENTS

The studies reported in this thesis were conducted in the Discipline of Medicine and the Department of Nuclear Medicine, PET and Bone Densitometry at the Royal Adelaide Hospital. While conducting the research reported in this thesis I was supported by a Royal Adelaide Hospital Dawes Postgraduate Scholarship.

First, and foremost, I would like to thank my two wonderful supervisors, Dr Christine-Feinle-Bisset and Professor Michael Horowitz. I have learnt an incredible amount during my PhD, not only about nutrition and the gastrointestinal tract, but also about myself. You have both provided me with an enormous amount of encouragement, guidance, support, wisdom, enthusiasm, friendship and the opportunity to travel overseas to present my work, which you have spent much time helping me perfect. I am privileged to have had the opportunity to study under two such inspiring and dedicated supervisors, and I have very much enjoyed working with you.

Secondly, to “team Christine Feinle-Bisset”, Tanya Little, Kate Feltrin and Ixchel Brennan (from the cool office). Wow, what a great bunch of girls - I could never have asked for such a great group to work with. Thank you so much for your friendship, support and encouragement. I will never forget the times we went out, the laughter, memories and the enormous amount of “idea-swapping”, which, when it comes down to it, got me though my studies and my thesis. Also, I would like to thank Diana Gentilcore and Karen Jones - you both never let me give up, and your patience and guidance to help me through what I thought was going to be an impossible task, will never be forgotten.
To my “pseudo mother figures”, Selena Doran and Franca Scopacasa - I will never forget our “chats”, not only about my studies and technical assistance, but “the bigger picture”. To Associate Professor Ian Chapmann, Professor Gary Wittert and Sue O’Connor, for providing me with employment during the last twelve months, while writing my thesis, and understanding that I was still writing my thesis. Also to my fellow employees who have all made me laugh, cry and made it easy for me to do “many” things at once. And to everyone else in the Discipline of Medicine I have not named, you have all made my last five years very memorable, and provided me with plenty of laughs and plenty of support.

To the visiting professors that I have been fortunate to work in collaboration with; Professor Trygve Hausken, Professor Odd Helge Gilja, Professor Jim Meyer, Professor Nick Talley and Professor Andre Smout - thank you all for teaching me the techniques used in this thesis and also for the time you spent giving advice regarding my studies.

To the statistician, Nancy Briggs - thank you for performing the numerous amounts of statistics throughout this thesis, especially for Chapter 9. Also to Antonietta Russo and Anne Maddox, for your assistance in the gastric emptying studies, Judith Wishart for performing the hormone assays, the team in ward Q7 for their technical support, and Professor Gerald Holtmann, for your assistance recruiting the functional dyspepsia patients.

To the individuals who volunteered their time in aid of my work. I would like to thank every one of you for trusting me enough to act as subjects in my studies. I have enjoyed
our conversations and most of your wacky stories - without you there would be no thesis…….

To my “girls” and to my “boys” - thank you all for putting up with me during the time I was writing my thesis. Your endless friendship, encouragement, kind words, smiling faces, and the way you all knew how to take me away, just for a drink (or plenty), and to twist my very malleable rubber arm to make me feel slightly human again, will never be forgotten. Especially to Dr (hah, I can say that now !) Renee Turner and Leah Panakera-Thorpe, who have both been there from the beginning of my university career, your overwhelming friendship, support and “ears”, have made my journey through my PhD a lot easier. Also to Matt Boundy for your no fuss approach at making me forget everything that goes wrong, to keep on going, and that everything in life is fixable !!!! I am forever grateful.

To my flat-mates, Diana, Katie, Tim and Lucas. I have had a lot of fun living with the four of you and I would sincerely like to thank you for giving me the tremendous amount of support you have, from cooking me dinner, telling me a joke at the most inappropriate time and to allow me to take over the back room with all my references and drafts of my thesis - the mess will be cleaned up soon!!!!

Finally, a special thank you to my family, especially to Mum, Dad, Laura, Nick and Nanna. Guess what, I am finished. You have all provided me with an enormous amount of emotional support, stability and good red wine - I could never ask for a better family.
PUBLICATIONS ARISING FROM THIS THESIS

The data presented in this thesis has formed the basis for the publications listed below:


